Urinary Bladder Cancer Clinical Trial
Official title:
Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer at Assuit University Hospital From 2015 to 2019(Hospital Based Study)
To pinpoint the clinical ,epidimiological factors and clinical outcomes in urinary bladder cancer patients attending to our department during 5 years period between 2015-2019.
Bladder cancer is the ninth most common cancer throughout the world. The incidence of bladder
cancer is three to four times greater in men than in women. However, women are diagnosed with
more advanced disease at presentation and have less favorable outcomes after treatment.
Statistical data show that between 2002 and 2012, worldwide, the number of bladder cancers
increased from 375.000 to about 430.000 , while the mortality increased from 145.000 patients
in 2002 up to 165.000 patients in 2012. In the United States, bladder cancer is the fourth
most common cancer in males with an age-adjusted incidence rate of 37.3/100,000 person years
(PY) using the US standard population.
In developed countries, over 90% of the bladder cancer cases diagnosed are transitional cell
carcinoma (TCC), with squamous cell carcinoma (SCC), adenocarcinomas, and rare types of
bladder cancer comprising the remaining 10% of bladder cancer cases.
Exposures to tobacco smoke, occupational toxins, and environmental sources of heavy metals
such as arsenic are the major reported risk factors for TCC.
Unlike TCC, the main risk factors for SCC are not environmental exposures, but exposure to
infectious agents. Age, smoking, tumor stage and the treatment modalities such as surgery and
adjuvant chemotherapy were proved to affect the overall survival in patients with urinary
bladder cancer. Our study may give an important evidence about clinical, epidemiological
factors and clinical outcomes in urinary bladder cancer patients at Assuit University
Hospital.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
| Withdrawn |
NCT05335707 -
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
|
||
| Completed |
NCT03998579 -
Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer
|
N/A | |
| Completed |
NCT02897765 -
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
|
Phase 1 | |
| Recruiting |
NCT05822934 -
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
|
Phase 3 | |
| Completed |
NCT06156787 -
Patterns of Urinary Bladder Cancer in Darfur, Suda
|
||
| Completed |
NCT02722538 -
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
|
Phase 1 | |
| Completed |
NCT02437539 -
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 1 | |
| Completed |
NCT02139371 -
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 0 | |
| Completed |
NCT03433924 -
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
|
||
| Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
| Completed |
NCT05946369 -
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
|
||
| Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
| Recruiting |
NCT05621837 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
||
| Recruiting |
NCT05644041 -
Intravesical Gemcitabine in Patients With NMIBC
|
Phase 2 | |
| Completed |
NCT04635566 -
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
|
N/A | |
| Recruiting |
NCT04861584 -
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
|
Phase 2 | |
| Completed |
NCT01836978 -
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
|
N/A | |
| Terminated |
NCT01374789 -
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
|
Phase 2 | |
| Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 |